Early-stage gene therapy indicates a 75% decrease in Huntington's disease advancement
An initial, investigational therapy demonstrates remarkable efficacy in decelerating Huntington’s disease, state UCL scientists. The FDA evaluation is anticipated in 2026.
Sourse: abcnews.go.com
